Good day, 360!

Here are our top investing ideas today. And don’t forget to join us in Market Masters – the hottest trading room around 🔥. Be the best prepared trader on the Street!

FOCUS LIST🔎

TNXP – Up over 50% in the pre-market after presenting data on the potential Mpox Vaccine TNX-801 in “Using Synthetic Biology to Battle Mpox” talk at Immunology Symposium at the University of Alberta

SMMT –  Up over 30% in pre after article published on BioPharma Dive stating Summit’s lung cancer drug showed ‘striking’ benefit over  Merck & Co.’s Keytruda.

TERN – Up over 25% in pre after announcing positive Phase 1 clinical trial results with TER-601 once-daily oral GLP-1R agonist for the treatment of obesity

*sponsored by VantagePoint 

You’ve heard it before… “Don’t beat around the bush”.

If you want to become a better options trader, I can’t wait to show you how to approach your trades directly and without hesitation.

Imagine your portfolio performance if you started buying weekly expirations dependent on future trends.

Now you can. Learn free here: From Entry to Exit: Supercharge Your Options Trading

HOTLIST🔥

TNXP – Up over 50% in the pre-market after presenting data on the potential Mpox Vaccine TNX-801 in “Using Synthetic Biology to Battle Mpox” talk at Immunology Symposium at the University of Alberta 

Tonix Pharmaceuticals Holding Corp. (TNXP) is a biopharmaceutical company that focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering.

In the pre-market this morning, the company announced that it had presented data on the potential Mpox Vaccine TNX-801 in “Using Synthetic Biology to Battle Mpox” talk at Immunology Symposium at the University of Alberta

Highlights include:

TNX-801 vaccination demonstrated efficacy in protecting animals from lethal challenge with clade I monkeypox and is in development as an mpox vaccine

New data show improved tolerability in immunocompromised animals and no evidence of spreading to blood or tissues even at high doses

Tonix’s synthetic horsepox vaccine platform has been selected by NIH’s Project NextGen for clinical testing

The stock traded up over 50% in the pre-market in reaction to the news.

The first target for bulls is the pre-market high at $0.26.

Beyond that $0.32, $0.40, $0.45 and $0.50 come into play.

Below $0.26, targets to the downside are $0.24, $0.22, $0.2057, $0.20, $0.18 and then a gap fill at $0.1425 come into play.

SMMT –  Up over 30% in pre after article published on BioPharma Dive stating Summit’s lung cancer drug showed ‘striking’ benefit over  Merck & Co.’s Keytruda.

Summit Therapeutics Inc. (SMMT)  is a biopharmaceutical company that focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom.

Over the weekend, an article was published on BioPharma Dive stating Summit’s lung cancer drug showed ‘striking’ benefit over  Merck & Co.’s Keytruda.

Data showed Summit’s drug held tumors at bay for a median of just over 11 months, compared to almost six months for those given Keytruda. The 5.3-month difference in progression-free survival equated to a statistically significant 49% reduction in the risk of cancer progression or death.

The stock traded up over 30% in reaction to the article and results.

The $15.50 area acted as support in the pre-market and will be an important level to watch.

Above it, targets to the upside are $16, $17, $18, $19 and then the pre-market high at $19.95.

Below $15.50, targets to the downside are $14, $12.50, $11.50, $10.50, $9.50, $8.50 and then a gap fill at $7.81.

TERN – Up over 25% in pre after announcing positive Phase 1 clinical trial results with TER-601 once-daily oral GLP-1R agonist for the treatment of obesity 

Terns Pharmaceuticals Inc. (TERN) is a clinical-stage biopharmaceutical company that develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity.

In the pre-market this morning, the company announced positive top-line data from its Phase 1 randomized, double-blind, placebo-controlled single and multiple-ascending dose (SAD and MAD) trial to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of TERN-601 dosed once-daily (QD) in healthy adults with obesity or overweight.

Highlights include:

Statistically significant mean weight loss up to 5.5% over 28 days (4.9% placebo adjusted)

Well-tolerated with no treatment-related dose interruptions, reductions, or discontinuations even with rapid dose titration

Distinct drug properties support potential to be a leading GLP-1R agonist

Plans to initiate Phase 2 clinical trial in 2025

The stock traded up over 25% in the pre-market in reaction to the news.

The first target for bulls is the pre-market high at $11.10.

Beyond that, $12, $13 and $14 come into play.

Below $11.10, targets to the downside are $10.50, $10, $9.50, $9. $8.50, $8 and then a gap fill at $7.81.

MARKET NEWS 📰

P.S. Make sure you text “RAGE” to (888) 404-5747 to get all of our latest HOT STOCK ideas!

Questions or concerns about our products? Email Support@360wallstreet.io © Copyright 2022, RagingBull